The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VIRI | +52.61% | -98.08% | -54.64% | -99% |
| S&P | +14.77% | +87.2% | +13.35% | +86% |
Virios Therapeutics, Inc. develops pharmaceutical products for fibromyalgia and other related conditions. The firm engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1, a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.
No news articles found for Dogwood Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$17.34K | 0.0% |
| Market Cap | $14.72M | 211.9% |
| Market Cap / Employee | $1.23M | 0.0% |
| Employees | 12 | 200.0% |
| Net Income | -$15,744.62K | -590.3% |
| EBITDA | -$15,791.78K | -586.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.13M | 396.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $120.21K | 0.0% |
| Short Term Debt | $54.57K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -81.05% | 71.0% |
| Return On Invested Capital | -93.28% | -6.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3,272.79K | -259.6% |
| Operating Free Cash Flow | -$3,272.79K | -259.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.88 | -0.66 | -0.51 | -0.81 | -116.34% |
| Price to Tangible Book Value | 0.88 | -0.08 | -0.10 | -0.15 | -100.39% |
| Enterprise Value to EBITDA | -10.41 | -20.51 | -24.72 | -7.30 | 527.07% |
| Return on Equity | -200.5% | -451.3% | -57.8% | -97.5% | -18.41% |
| Total Debt | $89.99M | $75.85M | $186.99K | $174.78K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
